Hamilton and Bionano Genomics Announce Commercial Availability of World’s First Ultra High Molecular Weight DNA Extraction Automation Solution for OGM
Since first announcing their collaboration at the
The companies continue to collaborate with select clinical research laboratories to test and further develop applications with different sample types for the use of the Long String VANTAGE and the Bionano Prep SP kits. Ongoing developments will focus on the automation of UHMW DNA extraction from BMA.
“We believe today marks an important day for anyone seeking to implement OGM at scale, with the announcement of commercial availability of the first automated solution for UMHW DNA isolation. The analysis of UHMW DNA can provide a more thorough way of detecting genomic aberrations that may be missed by traditional cytogenetic methods. Bionano and
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “can,” “expect,” “plan,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits and improvements resulting from the use of Hamilton’s Long String VANTAGE, or the ability of that system to reliably and consistently isolate high quality and sufficient quantity of UHMW DNA for use with OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; failure of the Long String VANTAGE to provide the anticipated benefits described in this press release; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
+1 (858) 888-7610
+1 (858) 366-3243
Source: Bionano Genomics